Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 Homozygotes
These strong correlations between structural preservation and clinical benefits of valiltramiprosate at the MCI stage support its efficacy and are consistent with its proposed mechanism of inhibiting amyloid oligomer formation, thereby potentially protecting neurons from synaptic dysfunction and neurodegeneration. Given the accelerated neurodegeneration in APOE4/4 patients, these findings suggest that intervention at the early stages of AD when neuronal reserve is higher, may be critical for valiltramiprosate to exert meaningful clinical effects alongside preservation of brain structure and volume.
Authors
- John A. Hey (ORCID: https://orcid.org/0000-0002-5104-6231)
- Emer MacSweeney
- Adem Albayrak (ORCID: https://orcid.org/0000-0002-6436-3164)
- Susan Flint
- Chris J. Conklin
- Margaret Bray
- David Watson
- Duygu Tosun (ORCID: https://orcid.org/0000-0001-5174-3910)
- Martin Tolar (ORCID: https://orcid.org/0000-0002-3910-091X)
- Patrick Kesslak
- Aidan Power
- Earvin Liang
- Susan Abushakra
- Luc Bracoud
- Anton P. Porsteinsson
- P. Murali Doraiswamy
- Sharon Cohen
- Marwan N. Sabbagh
Institutions
- Department of Health and Social Care (GB)
- San Francisco VA Medical Center (US)
- Barrow Neurological Institute (US)
- Duke University (US)
- Toronto Public Health (CA)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Houston Perinatal Associates (US)
- Framingham State University (US)
- University of Rochester (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108827
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00